Source and scope
This summary is bounded to the recommendations, population and decisions covered by Canadian Schizophrenia Guidelines. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CPA schizophrenia
Source-attributed clinical priorities
- Arrange early coordinated assessment for first-episode psychosis and address immediate risk, substance use and medical mimics.
- Pair antipsychotic treatment with psychosocial, family, vocational and physical-health care.
- Monitor cardiometabolic and movement adverse effects and assess adherence before labelling treatment resistance.
- Reduce the duration of untreated psychosis by connecting a first episode directly to an early-intervention service.
sources for this section:CPA schizophrenia
Practical assessment and management workflow
1
Assess hallucinations, delusions, disorganization, negative symptoms, cognition, mood, substances and functional decline.
2
Perform physical and neurologic examination and targeted investigations for intoxication, withdrawal or medical mimics.
3
Agree on antipsychotic choice with attention to prior response, metabolic risk, movement effects and formulation preference.
4
Review response, adherence, family needs, housing, education or work and physical health through coordinated follow-up.
sources for this section:CPA schizophrenia
Safety, red flags and urgent escalation
- Escalate command hallucinations with intent, severe agitation, catatonia, inability to eat or drink, or acute medical toxicity.
- Monitor weight, waist, blood pressure, glucose, lipids and movement symptoms from treatment initiation.
- Suspected neuroleptic malignant syndrome requires immediate drug cessation and emergency care.
sources for this section:CPA schizophrenia
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CPA schizophrenia
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CPA schizophrenia
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Canadian Psychiatric AssociationCanadian Schizophrenia Guidelinesaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.